An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. is a phase 2 interventional study registered as NCT07282262 by Peking Union Medical College Hospital, with a registry enrolment figure of 300 participants, started 2024-05-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: Ivosidenib, Lenvatinib, PD-1/PD-L1 inhibitor. Conditions listed: Biliary Tract Cancer. Sites: China. No results are recorded here; the registry entry is the source.